Modality
Peptide
MOA
RAS(ON)i
Target
B7-H3
Pathway
Amyloid
NBLGS
Development Pipeline
Preclinical
Oct 2017
→ Oct 2030
PreclinicalCurrent
NCT07005279
175 pts·NB
2017-10→2030-10·Terminated
175 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-143mo awayPDUFA· LGS
2030-10-034.5y awayInterim· NB
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Termina…
Catalysts
PDUFA
2026-07-14 · 3mo away
LGS
Interim
2030-10-03 · 4.5y away
NB
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07005279 | Preclinical | NB | Terminated | 175 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 |